Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax vs Pomalidomide in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
NCT03539744Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2018
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of venetoclax in multiple myeloma (MM), sponsored by AbbVie Inc.. Started Oct 2018; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03539744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03539744.